ストックスクリーナーアプリを入手
29.34
5.05%
1.41
前日終値:
$27.93
開ける：
$27.82
24時間の取引高:
1.07M
Relative Volume:
0.92
時価総額：
$1.68B
収益：
$199.89M
当期純損益:
$52.48M
株価収益率:
34.52
EPS:
0.85
ネットキャッシュフロー:
$61.15M
1週間 パフォーマンス:
+10.68%
1か月 パフォーマンス:
-15.40%
6か月 パフォーマンス:
+209.49%
1年 パフォーマンス:
+160.34%
1日の値動き範囲:
$27.53
$29.46
1週間の範囲:
$25.31
$29.46
52週間の値動き範囲:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
STOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
29.34 | 1.60B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
(STOK) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Why Stoke Therapeutics Inc. stock remains undervaluedMarket Risk Report & Short-Term High Return Ideas - newser.com
Can Stoke Therapeutics Inc. stock sustain institutional interest2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
How Stoke Therapeutics Inc. stock valuations compare to rivalsProduct Launch & Verified Momentum Stock Alerts - newser.com
Can Stoke Therapeutics Inc. stock surprise with earnings upsideQuarterly Profit Report & High Conviction Buy Zone Alerts - newser.com
Can Stoke Therapeutics Inc. stock resist sector downturns2025 Top Decliners & Intraday High Probability Alerts - newser.com
Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares - MarketBeat
Does Stoke Therapeutics Inc. show high probability of reboundJuly 2025 Gainers & Weekly High Return Forecasts - newser.com
Is Stoke Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Weekly High Conviction Ideas - newser.com
Live market analysis of Stoke Therapeutics Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Why Stoke Therapeutics Inc. stock attracts high net worth investorsBear Alert & Fast Moving Stock Trade Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6%Still a Buy? - MarketBeat
Will Stoke Therapeutics Inc. stock maintain momentum in 20252025 Analyst Calls & Risk Managed Investment Signals - newser.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC - MarketBeat
Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)November 18, 2025 - BioSpace
What technical models suggest about Stoke Therapeutics Inc.’s comeback2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Director Adrian R. Krainer Sells Over 40,000 Shares - TradingView
Dir Krainer Sells 40,472 ($1.1M) Of Stoke Therapeutics Inc [STOK] - TradingView
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Could Endpoint Choices in the EMPEROR Trial Reveal a Strategic Shift for Stoke Therapeutics (STOK)? - simplywall.st
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - The Manila Times
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):